Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study
(2022)
Journal Article
Monk, P. D., Brookes, J. L., Tear, V. J., Batten, T. N., Mankowski, M., Adzic-Vukicevic, T., Crooks, M. G., Dosanjh, D. P., Kraft, M., Brightling, C. E., Gabbay, F. J., Holgate, S. T., Djukanovic, R., & Wilkinson, T. M. (2023). Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study. ERJ Open Research, 9(2), Article 00605-2022. https://doi.org/10.1183/23120541.00605-2022
Background Despite the availability of vaccines and therapies, patients are being hospitalised with coronavirus disease 2019 (COVID-19). Interferon (IFN)-β is a naturally occurring protein that stimulates host immune responses against most viruses, i... Read More about Nebulised interferon-β1a (SNG001) in hospitalised COVID-19: SPRINTER phase III study.